SEVELAMER HYDROCHLORIDE
Clinical safety rating: safe
Can decrease the absorption of many other drugs administer other drugs 1 hour before or 3 hours after Can cause GI side effects and hypocalcemia.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
| Metabolism | Sevelamer hydrochloride is not absorbed systemically and is not metabolized. It is excreted unchanged in the feces. |
| Excretion | Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs. |
| Half-life | Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life. |
| Protein binding | Not applicable; sevelamer is not absorbed and does not bind to plasma proteins. |
| Volume of Distribution | Not applicable; sevelamer is not absorbed and remains within the gastrointestinal lumen; thus, it does not have a volume of distribution. |
| Bioavailability | Sevelamer hydrochloride is not absorbed and has negligible systemic bioavailability (<0.001% absorbed). It acts locally in the GI tract. |
| Onset of Action | Sevelamer hydrochloride begins to bind dietary phosphate immediately upon ingestion; however, measurable reductions in serum phosphate may take up to 2 weeks of regular dosing to achieve clinical effect. |
| Duration of Action | The binding action lasts as long as the drug remains in the gastrointestinal tract, typically for the duration of the dosing interval (e.g., 8 hours with each meal). The effect on serum phosphate levels is sustained with continued administration. |
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment; drug is not systemically absorbed. Contraindicated in patients with hypophosphatemia or bowel obstruction. |
| Liver impairment | No dose adjustment needed; drug is not metabolized by the liver and is not absorbed systemically. |
| Pediatric use | Children ≥6 years: initial 800-1600 mg/day divided with meals, titrate based on serum phosphorus. Maximum 13 g/day. Safety and efficacy not established in children <6 years. |
| Geriatric use | No specific dose adjustment; use with caution due to increased risk of gastrointestinal adverse effects. Monitor serum phosphorus and calcium levels regularly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Can decrease the absorption of many other drugs administer other drugs 1 hour before or 3 hours after Can cause GI side effects and hypocalcemia.
| FDA category | Animal |
| Breastfeeding | Not absorbed systemically, so excretion into breast milk is negligible. M/P ratio is not applicable. Compatible with breastfeeding. |
| Teratogenic Risk | Sevelamer hydrochloride is not absorbed systemically; therefore, no direct fetal exposure is expected. No teratogenic effects have been observed in animal studies. Risk cannot be excluded, but based on mechanism, risk is low. |
■ FDA Black Box Warning
None.
| Common Effects | Nausea |
| Serious Effects |
["Hypersensitivity to sevelamer hydrochloride or any component of the formulation","Bowel obstruction","Patients with hypophosphatemia","Concurrent use with ciprofloxacin (reduces its absorption)"]
| Precautions | ["May cause bowel obstruction, perforation, or impaction, especially in patients with gastrointestinal disorders or prior surgery","Monitor for gastrointestinal bleeding and severe constipation","May cause decreased absorption of fat-soluble vitamins (A, D, E, K) and folic acid","May cause metabolic acidosis in susceptible patients","Use with caution in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders"] |
Loading safety data…
| Fetal Monitoring | Monitor serum phosphate, calcium, and bicarbonate levels periodically. No specific fetal monitoring required. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. No human data available. |